Følg Karo Pharma

Pressemeldinger 3 treff

New license agreement with AFT Pharmaceuticals for Nordic rights to groundbreaking product line within Pain Management

New license agreement with AFT Pharmaceuticals for Nordic rights to groundbreaking product line within Pain Management

Pressemeldinger   •   jan 12, 2017 10:20 CET

Weifa has in-licensed a patented fixed-combination product line within pain management from AFT Pharmaceuticals (“AFT”) in New Zealand. The agreement gives rights to commercialize the products in the entire Nordic region (Norway, Sweden, Denmark, Finland and Iceland).

Weifa ASA to launch  a new medicinal product for  insomnia in Norway

Weifa ASA to launch a new medicinal product for insomnia in Norway

Pressemeldinger   •   aug 10, 2016 14:58 CEST

Weifa ASA is pleased to announce the launch of Zonat® tablets, which is indicated for short-term symptomatic treatment of occasional insomnia in adults over 18 years old. Zonat® contains the antihistamine doxylamine, which is well established as a non-prescription (OTC) product for occasional insomnia in several European countries. In Norway Zonat® will require medical prescription.

Distribution agreement in Finland for unique pain products

Distribution agreement in Finland for unique pain products

Pressemeldinger   •   jun 06, 2016 13:30 CEST

Weifa has signed a 5-year distribution agreement with the Fysioline Group (Finland). The agreement covers several of Weifa’s most recently launched products within the pain category, and can be extended to include additional products.